IP
IBRX icon

Intellectus Partners’s ImmunityBio IBRX Stock Holding History

Intellectus Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed – – 377
2018
Q3 		$0 Hold
100
– – ﹤0.01% 595
2018
Q2 		$0 Hold
100
– – ﹤0.01% 601
2018
Q1 		$0 Hold
100
– – ﹤0.01% 611
2017
Q4 		$0 Hold
100
– – ﹤0.01% 641
2017
Q3 		$1K Hold
100
– – ﹤0.01% 755
2017
Q2 		$1K Hold
100
– – ﹤0.01% 740
2017
Q1 		$0 Hold
100
– – ﹤0.01% 702
2016
Q4 		$1K Buy
+100
New +$667 ﹤0.01% 663

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Intellectus Partners's IBRX Position: Q4 2018 in Review

Intellectus Partners sold out of ImmunityBio (IBRX) in Q4 2018, closing a stake of 100 shares.

Intellectus Partners first reported a position in IBRX in Q4 2016 and held it in 8 quarters. The position peaked at $1K in Q3 2017. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2018.

  • Intellectus Partners reported no remaining ImmunityBio position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 100 ImmunityBio shares in Q4 2018.
  • Intellectus Partners first reported a position in ImmunityBio in Q4 2016 and held it in 8 quarters.
  • Intellectus Partners's ImmunityBio position peaked at $1K in Q3 2017.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.